louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02884258: IVF Outcome After Bariatric Surgery
Official title: In Vitro Fertilization (IVF) Outcome After Bariatric Surgery: a Multicentric Case-control Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility
Obesity
Keywords: Assisted Reproductive Technology
Obesity
Bariatric Surgery
Infertility
Fertility Preservation
Lead sponsor: Clinique Mathilde
Sponsor class: OTHER
First posted: 2016-08-30
Enrollment: 249
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women underoing IVF and having undergone bariatric surgery

Brief summary: This case-control study compares IVF results and live birth rates in women undergoing IVF with a history of bariatric surgery as compared to 2 age-matched control groups composed of (A) non-operated women matched on cases' post-operative BMI (controls 1) and (B) non-operated severely obese women (controls 2).

Detailed description: A preliminary study in the participating center showed a trend to lower ovarian response to stimulation and live birth rates after bariatric surgery compared to weight-matched patients. However, statistical significance was not reached, as the sample size was small.

The aim of the research project is to study the ovarian response and live birth rates of this bariatric surgery population, with a sufficient number of patients, in order to reach higher statistical power. This case-control study will involve 3 IVF (in-vitro fertilization) centers in France . All patients undergoing IVF with a history of bariatric surgery will be included from January 2012. Each case will be matched for BMI and age to the 2 next patients without bariatric surgery history and undergoing IVF and to one non-operated severely obese woman. Surgery procedures include sleeve gastrectomies and by-passes. The IVF results and live birth rates will be compared between the three groups.

Eligibility criteria: Inclusion Criteria:

* Undergoing IVF and with a history of bariatric surgery

Primary outcomes:
measure: Live birth rates
timeFrame: nine months after embryo transfer
Secondary outcomes:
measure: average number of mature oocytes obtained
timeFrame: The day of oocyte retrieval in the case of IVF with sperm injection (ICSI) just after decoronisation, or on day one after oocyte retrieval in classical IVF. Oocyte retrieval occurs 36 hours after hCG injection after an ovarian stimulation protocol.
Other outcomes:
Locations:
city: Rouen
country: France
facility: Clinique Mathilde
Study officials:
References:
citation: Grzegorczyk-Martin V, Freour T, De Bantel Finet A, Bonnet E, Merzouk M, Roset J, Roger V, Cedrin-Durnerin I, Wainer R, Avril C, Landais P. IVF outcomes in patients with a history of bariatric surgery: a multicenter retrospective cohort study. Hum Reprod. 2020 Dec 1;35(12):2755-2762. doi: 10.1093/humrep/deaa208.
Clinical trial NCT01082458: Comparison of Lidocaine and Remifentanil for the Effect on Responses to the Endotracheal Tube During Emergence From General Anesthesia
Official title: Comparison of Lidocaine and Remifentanil for the Effect on Responses to the Endotracheal Tube During Emergence From General Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thyroidectomy
Keywords: Patients scheduled to undergo thyroidectomy
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2010-03-08
Enrollment: 67
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: PREVENTION

Brief summary: Target concentration infusion(TCI) of remifentanil (2.0ng/ml) suppresses the cough induced by endotracheal tube more effectively than intravenous administration of lidocaine (1.5mg/kg).


Eligibility criteria: Inclusion Criteria:

* Females older than 20 years old

Exclusion Criteria:

* Patients with acute or chronic respiratory disease, hypertension, gastro-esophageal reflux disease, having preoperative sedatives or mucolytics, and current smoker.

Primary outcomes:
measure: Comparison of lidocaine and remifentanil for the effect on responses to the endotracheal tube during emergence from general anesthesia
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
References:
Clinical trial NCT03430258: High-flow Nasal Cannula Oxygen Therapy With the Chest Trauma Patients
Official title: High-flow Nasal Cannula Oxygen Therapy With the Chest Trauma Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Blunt Thoracic Injury
Lung Ultrasound Score
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2018-02-12
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This prospective randomized controlled study was conducted in the emergency intensive care units (EICU) of the second affiliated hospital Zhejiang university school of medicine, a large tertiary university hospital in HangZhou, China.The aim of this randomized study was to compare the effectiveness of high-flow nasal cannula with conventional oxygen therapy in ICU patients with blunt thoracic injury.

Detailed description: This prospective randomized controlled study was conducted in the emergency intensive care units (EICU) of the second affiliated hospital Zhejiang university school of medicine, a large tertiary university hospital in HangZhou, China.The aim of this randomized study was to compare the effectiveness of high-flow nasal cannula with conventional oxygen therapy in ICU patients with blunt thoracic injury.

Eligibility criteria: Inclusion Criteria:

- The trauma registry was used to identify patients with moderate to severe blunt thoracic injury (abbreviated injury scale (AIS) chest score ≥3) admitted to the ICU

Exclusion Criteria:

1. had intubation and used the mechanical ventilation within 2 hours
2. had the emergency surgerys within 2 hours
3. patients can not accessed by transthoracic lung ultrasound because of the sever aerodermectasia or pneumothorax
4. the Glasgow Coma Scale \<8

Primary outcomes:
measure: compare the effectiveness of high-flow nasal cannula with conventional oxygen therapy in ICU patients with blunt thoracic injury.
timeFrame: 72 hours
Secondary outcomes:
measure: number of days in ICU
timeFrame: 7 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03522558: Medical Nutrition Therapy for Medically Complex Infants in the Pediatric Outpatient Setting
Official title: Medical Nutrition Therapy for Medically Complex Infants in the Pediatric Outpatient Setting. A Quality Improvement Project
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Growth Failure in Medically Complex Infants
Growth Failure
Malnutrition in Medically Complex Infants
Malnutrition
Nutrition in Medically Complex Infants
Nutrition
Nutrition Disorder, Infant
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2018-05-11
Enrollment: 200
Sex: ALL
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare standardized nutrition therapy provided by a registered dietitian (RD) at regularly scheduled intervals to usual care in terms of the ability to improve growth parameters in medically complex infants in the pediatric outpatient setting.


Eligibility criteria: Inclusion Criteria:

* Patients who are admitted between July, 2018 and June, 2019 to the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UT Health from a neonatal intensive care unit (NICU)

Exclusion Criteria:

* short bowel syndrome,
* requiring parenteral nutrition (PN)
* active cancer

Primary outcomes:
measure: Number of participants with a 20% improvement in growth velocity at 1 year corrected gestational age (CGA)
timeFrame: 4 months corrected gestational age (CGA)
measure: Number of participants with a 20% improvement in growth velocity at 1 year corrected gestational age (CGA)
timeFrame: 8 months corrected gestational age (CGA)
measure: Number of participants with a 20% improvement in growth velocity at 1 year corrected gestational age (CGA)
timeFrame: 12 months corrected gestational age (CGA)
measure: Number of participants with a 20% improvement in growth velocity at 1 year corrected gestational age (CGA)
timeFrame: 1 year corrected gestational age (CGA)
Secondary outcomes:
measure: Number of participants with growth failure
timeFrame: 1 year corrected gestational age (CGA)
measure: Number of participants who are malnourished
timeFrame: 1 year corrected gestational age (CGA)
measure: Severity of malnutrition as assessed by the AND/ASPEN criteria
timeFrame: 1 year corrected gestational age (CGA)
measure: Number of emergency department visits
timeFrame: 1 year corrected gestational age (CGA)
measure: Number of hospitalizations
timeFrame: 1 year corrected gestational age (CGA)
measure: Length of stay
timeFrame: about 3 to 7 days
Other outcomes:
Locations:
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Candice R Poland, MS, RD, LD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00243958: Aluminum and Auditory Function in ESRD
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: End-Stage Renal Disease (ESRD)
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-10-25
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: OTHER

Brief summary: Hearing impairment either clinical or subclinical is a characteristic of some renal disease patients. The hearing impairment could be result from specific etiologies or chronic renal failure itself. The causes of hearing impairment in renal disease patients ranged from drugs intoxication in both auditory and renal function, like gentamycin or isoniazid, congenital disease like Alport syndrome or other collagen-defective renal disease, or just aging related. End-stage renal disease (ESRD) patients are special in many parts to general population who have hearing impairment. First, inflammation in ESRD patients is well-documented, second, they suffered from various underlying diseases which auditory function was potentially impaired, third, they need to undergo renal replacement therapy either hemodialysis (HD) or peritoneal dialysis (PD) to maintain their life. Dialysis itself was found to be a cause of hearing impairment, too. The biochemical change and constitutive inflammation status are thought to be implicated in the pathogenesis of hearing impairment in ESRD patients. Aluminum (Al) is a well-documented heavy metal, which predisposes to Alzheimer's disease, dementia or some neurologic diseases. Al intoxication is very rare in general health population but elevated serum Al level is easily found in ESRD patients since they can not excrete Al by damaged kidneys and dialyzers. Inner ear per se is a neurologic tissue, so if serum Al level in ESRD patients has any association in their haring function needs to be studied.


Eligibility criteria: Inclusion Criteria:

ESRD patients and healthy volunteers, without history of occupational noise exposure, ear infection, ear surgery, active systemic infection, previous ototoxic drugs exposure or congenital hearing defect

Exclusion Criteria:

Unsuitable to undergo hearing test, with history of occupational noise exposure, ear infection, ear surgery, active systemic infection, previous ototoxic drugs exposure or congenital hearing defect

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Dou-Liu
country: Taiwan
facility: National Taiwan University Hospital, Yun-Lin Branch
state: Yun-Lin
city: Dou-Liu
country: Taiwan
facility: National Taiwan University Hospital, Yun-Lin Branch
state: Yun-Lin
Study officials:
affiliation: National Taiwan University Hospital
name: Kwan-Dun Wu, MD. PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04649658: Pronation in COVID-19 Patients Undergoing Non Invasive Respiratory Support
Official title: Awake Prone Position in Critical and Severe COVID-19 Patients Undergoing Noninvasive Respiratory Support: a Retrospective Multicenter Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Keywords: Spontaneous breathing
Awake pronation
COVID-19
Respiratory failure
Lead sponsor: University of Modena and Reggio Emilia
Sponsor class: OTHER
First posted: 2020-12-02
Enrollment: 93
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients aged ≥18 and \< 80 years old admitted to the two respiratory intensive care units for severe and critical COVID-19 pneumonia between March 1st, 2020 and June 1st, 2020.

Brief summary: Pronation seems feasible and effective in improving blood oxygenation in patients with COVID-19 pneumonia. Data are lacking on the effects of pronation on clinical outcome in this subset of patients.


Eligibility criteria: Inclusion Criteria:

Inclusion Criteria

* patients aged ≥18 and \< 80 years old
* acute respiratory failure

Exclusion Criteria:

* endotracheal intubation performed within the first 24 hours from admission,
* ceiling of escalation of intensive care
* do not intubate order as expressed by patient willing or upon clinical judgement
* missing core data at medical record analysis (clinical features at baseline, pronation information, type and time of ventilatory support required, mortality, need for tracheostomy, length of respiratory intensive care unit and hospital stay).

Primary outcomes:
measure: Endotracheal intubation
timeFrame: 28 days
Secondary outcomes:
measure: Mortality
timeFrame: 28 days
measure: Tracheostomy
timeFrame: 28 days
measure: Length of Respiratory Intensive Care Unit stay
timeFrame: 60 days
measure: Length of Hospital stay
timeFrame: 60 days
Other outcomes:
Locations:
city: Modena
country: Italy
facility: Azienda Ospedaliero Universitaria Policlinico di Modena
Study officials:
References:
Clinical trial NCT06737458: Serratus Anterior Plane Block Versus Erector Spinae Plane Block With Dexmedetomidine Added to Bupivacaine for Ultrasound-Guided Pain Management After Mastectomy
Official title: Serratus Anterior Plane Block Versus Erector Spinae Plane Block With Dexmedetomidine Added to Bupivacaine for Ultrasound-Guided Pain Management After Mastectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Serratus Anterior Plane Block
Erector Spinae Plane Block
Dexmedetomidine
Bupivacaine
Ultrasound
Pain Management
Mastectomy
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2024-12-17
Enrollment: 40
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aimed to compare the serratus plane block versus the erector spinae plane block with dexmedetomidine added to bupivacaine for acute pain management after breast surgeries.

Detailed description: Approximately 40-60% of breast surgery patients endure severe acute postoperative pain, with over 10% of patients experiencing severe pain for six to twelve months (post-mastectomy pain syndrome).

Dexmedetomidine has analgesic properties, which could be related to the stimulation of α2 adrenoceptors, inhibition of nerve conduction through C and Aδ fibers, and the local release of encephalin.

Serratus plane block (SPB) is an effective approach for breast surgery analgesia due to its simplicity of delivery, minimal risk of adverse effects, and ability to provide significant pain relief.

The erector spinae plane block (ESPB) is one of the emerging regional techniques for managing postoperative pain. ESPB can be given unilaterally during modified radical mastectomy.

Eligibility criteria: Inclusion Criteria:

* Women aged \>20 years.
* Patient's approval.
* American Society of Anesthesiologists (ASA) physical status I-II.
* Patients underwent breast surgeries.

Exclusion Criteria:

* Known allergy to local anesthetics, opioids, or dexmedetomidine medications.
* Advanced heart block, ventricular dysfunction.
* Skin infection at the site of injection.
* Pre-existing chronic pain.
* Coagulopathies, significant liver or renal insufficiency.

Primary outcomes:
measure: Total dose of pethidine consumption
timeFrame: 24 hours postoperatively
Secondary outcomes:
measure: Intraoperative fentanyl consumption
timeFrame: Intraoperatively
measure: Heart rate
timeFrame: Every 15 minutes until the end of the surgery (Up to 2 hours)
measure: Mean arterial pressure
timeFrame: Every 15 minutes until the end of the surgery (Up to 2 hours)
measure: Degree of pain
timeFrame: 24 hours postoperatively
measure: Incidence of complications
timeFrame: 24 hours postoperatively
Other outcomes:
Locations:
city: Kafr Ash Shaykh
country: Egypt
facility: Kafrelsheikh University
state: Kafrelsheikh
Study officials:
References:
Clinical trial NCT05961358: Auxiliary Anesthesia Technique for Extracting Advanced Hemodynamic Parameters Based on Peripheral Arterial Waveform Photography
Official title: Auxiliary Anesthesia Technique for Extracting Advanced Hemodynamic Parameters Based on Peripheral Arterial Waveform Photography
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Anesthesia
Keywords: arterial blood pressure
cardiac output
advanced hemodynamic
mobile Applications
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2023-07-27
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants for this study will be recruited at the Second Affiliated Hospital Zhejiang University School of Medicine. The study participants will be adult general anesthesia patients.

Brief summary: In this study, the arterial blood pressure waveform was digitized by snapshots or videos of the patient monitor to further estimate advanced hemodynamic parameters, so as to realize continuous and automatic monitoring of advanced hemodynamics on mobile devices to assist anesthesia, with a view to developing an Android/iOS application for mobile devices and application in patient management.


Eligibility criteria: Inclusion Criteria:

* Invasive blood pressure monitoring
* Aged 18-65 years
* ASA class I-III

Exclusion Criteria:

* Spontaneous breathing
* Prone position
* Non-radial artery cannulation
* Aortic regurgitation
* Heart arrhythmia
* Heart rate \> 100/min
* Intra-aortic balloon pump
* Peripheral vascular disease
* Body weight \< 40 kg

Primary outcomes:
measure: Comparison of mobile device analysis results with Vigileo analysis results
timeFrame: 1 day
measure: Comparison of arterial waveform collected directly analysis results and Vigileo analysis results
timeFrame: 1 day
measure: Comparison of arterial waveform collected directly analysis results and mobile device analysis results
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: The Second Affiliated Hospital of Zhejiang University anesthesiology department
state: Zhejiang
Study officials:
References:
Clinical trial NCT03371758: Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo
Official title: Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo and Healthy Control; Comparative Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Autophagy
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-12-13
Enrollment: 40
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.


Eligibility criteria: Inclusion Criteria:

* • Patients with non-segmental vitiligo whether active or stable.

  * Age above 12 years.
  * Both sexes.

Exclusion Criteria:

* • Patients should not use any topical or systemic treatment at least 6 weeks before inclusion into the study.

  * Patients having other autoimmune disease, heart disease, liver disease, kidney disease, neurological disorder, cancer, active infection or any chronic disease.
  * Pregnancy or breast feeding for female patients.

Primary outcomes:
measure: Expression of LC3-I, LC3-II & Beclin 1 in vitiligo patients
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Maha Fathy Elmasry
Study officials:
References: